SCHEMBL2771265

SCHEMBL2771265

CCOC(=O)C(O)C(O)=C(C)C

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.44
LMNA P02545 2/20 0.44
HSD17B10 Q99714 1/20 0.44
ALOX15 P16050 1/20 0.37
MGAM O43451 1/20 0.37
GAA P10253 1/20 0.37
SI P14410 1/20 0.37
MGAM2 Q2M2H8 1/20 0.37
SOAT1 P35610 1/20 0.37
PIN1 Q13526 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
HCAR2 Q8TDS4 1/20 0.35
MEN1 O00255 1/20 0.35
NPC1 O15118 1/20 0.35
KMT2A Q03164 1/20 0.35
TRPA1 O75762 1/20 0.34
GLO1 Q04760 1/20 0.34
CPB2 Q96IY4 1/20 0.34
CYP2D6 P10635 1/20 0.33
CYP2C9 P11712 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1249258 0.80 ALDH1A1 (0.53) ALDH1A1LMNAHSD17B10ALOX15MGAM
SCHEMBL6667841 0.78 ALDH1A1 (0.46) ALDH1A1LMNAHSD17B10ALOX15MGAM
SCHEMBL903306 0.78 ALDH1A1 (0.50) ALDH1A1LMNAHSD17B10ALOX15MGAM
SCHEMBL4667159 0.76 SMN1; SMN2 (0.39) ALDH1A1KMT2A
SCHEMBL901093 0.74 ALDH1A1 (0.46) ALDH1A1LMNAHSD17B10ALOX15MGAM
Acetic Acid SCHEMBL28254246 0.73 ALDH1A1 (0.50) ALDH1A1LMNAHSD17B10ALOX15MGAM
SCHEMBL27730937 0.71 MGAM (0.46) ALDH1A1LMNAHSD17B10ALOX15MGAM
SCHEMBL14139334 0.71 ALOX15 (0.52) ALDH1A1LMNAHSD17B10ALOX15MGAM
Acetic Acid SCHEMBL1660055 0.71 ALDH1A1 (0.48) ALDH1A1LMNAHSD17B10ALOX15MGAM
Acetic Acid SCHEMBL4138880 0.71 ALDH1A1 (0.48) ALDH1A1LMNAHSD17B10ALOX15MGAM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1949893-B1 Quinazoline derivatives useful for the treatment of peripheral arterial disease and as phosphodiesterase inhibitors SHIRE BIOPHARMACEUTICALS HOLDI (GB) 2010-10-13 EP disclosed
US-7700608-B2 Quinazoline derivatives and their use in the treatment of thrombocythemia SHIRE HOLDINGS AG (CH) 2010-04-20 US disclosed
US-20100093772-A1 QUINAZOLINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF THROMBOCYTHEMIA SHIRE HOLDINGS AG (CH) 2010-04-15 US disclosed
EP-1781296-B1 QUINAZOLINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF THROMBOCYTHEMIA SHIRE HOLDINGS AG (CH) 2010-03-10 EP disclosed
EP-1781296-A4 QUINAZOLINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF THROMBOCYTHEMIA SHIRE HOLDINGS AG (CH) 2008-08-20 EP disclosed
EP-1778235-A4 QUINAZOLINE DERIVATIVES USEFUL FOR THE TREATMENT OF PERIPHERAL ARTERIAL DISEASE AND AS PHOSPHODIESTERASE INHIBITORS SHIRE HOLDINGS AG (CH) 2008-08-20 EP disclosed
EP-1949893-A2 Quinazoline derivatives useful for the treatment of peripheral arterial disease and as phosphodiesterase inhibitors Shire Holdings AG (CH) 2008-07-30 EP disclosed
EP-1781296-A2 QUINAZOLINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF THROMBOCYTHEMIA Shire Holdings AG (CH) 2007-05-09 EP disclosed
EP-1778235-A2 QUINAZOLINE DERIVATIVES USEFUL FOR THE TREATMENT OF PERIPHERAL ARTERIAL DISEASE AND AS PHOSPHODIESTERASE INHIBITORS Shire Holdings AG (CH) 2007-05-02 EP disclosed
US-20060052601-A1 Quinazoline derivatives and their use in the treatment of thrombocythemia SHIRE HOLDINGS AG (CH) 2006-03-09 US disclosed
WO-2006017822-A2 QUINAZOLINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF THROMBOCYTHEMIA SHIRE HOLDINGS AG (CH) 2006-02-16 WO disclosed
WO-2006017823-A2 QUINAZOLINE DERIVATIVES USEFUL FOR THE TREATMENT OF PERIPHERAL ARTERIAL DISEASE AND AS PHOSPHODIESTERASE INHIBITORS SHIRE HOLDINGS AG (CH) 2006-02-16 WO disclosed
US-20060030574-A1 Quinazoline derivatives useful for the treatment of peripheral arterial disease and as phosphodiesterase inhibitors SHIRE HOLDINGS AG (CH) 2006-02-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060052601-A1 Quinazoline derivatives and their use in the treatment of thrombocythemia ABL1, MPL, PFKP ALDH1A1 1401/4885LMNA 2769/4885HSD17B10 3698/4885
US-20100093772-A1 QUINAZOLINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF THROMBOCYTHEMIA ABL1, MPL, PFKP ALDH1A1 1401/4885LMNA 2769/4885HSD17B10 3698/4885
US-20060030574-A1 Quinazoline derivatives useful for the treatment of peripheral arterial disease and as phosphodiesterase inhibitors PDE3B, PDE3A, PDE5A ALDH1A1 952/4885LMNA 2603/4885HSD17B10 921/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.